Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PTN
PTN logo

PTN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Palatin Technologies Inc (PTN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
11.720
1 Day change
-4.33%
52 Week Range
31.000
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Palatin Technologies Inc (PTN) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock exhibits bearish technical indicators, lacks positive trading signals, and has no recent news or significant catalysts to drive growth. Given the absence of strong financial data and a neutral sentiment from insiders and hedge funds, it is better to hold off on investing in this stock until clearer positive signals emerge.

Technical Analysis

The technical indicators for PTN show a bearish trend. The MACD is negatively expanding (-0.0401), the RSI is at 22.021 (neutral zone), and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 11.761), with resistance levels at R1: 14.429 and R2: 15.253.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
5

Positive Catalysts

  • NULL identified. No recent news or significant events to act as positive catalysts. Analysts maintain a Buy rating but have lowered the price target due to delays in product development.

Neutral/Negative Catalysts

  • Bearish technical indicators, lack of recent positive news, and delays in product development as noted by analysts. The stock also lacks significant trading trends from insiders or hedge funds.

Financial Performance

No financial data available for analysis. The company's latest quarter financials could not be assessed.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Alliance Global maintains a Buy rating but lowered the price target from $50 to $47.50 due to delays in product launch and a shift to a next-generation compound. No material changes were made to near-term forecasts.

Wall Street analysts forecast PTN stock price to rise
1 Analyst Rating
Wall Street analysts forecast PTN stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.250
sliders
Low
50
Averages
50
High
50
Current: 12.250
sliders
Low
50
Averages
50
High
50
Alliance Global
Buy
maintain
$50
AI Analysis
2026-05-14
Reason
Alliance Global
Price Target
$50
AI Analysis
2026-05-14
maintain
Buy
Reason
Alliance Global lowered the firm's price target on Palatin to $47.50 from $50 and keeps a Buy rating on the shares. After the company's quarterly report, the firm made no material changes to near-term forecasts, but did push out timing of product launch by one year to reflect the shift to a next-generation compound over PL7737 as Palatin is shifting its oral pursuit of an MC4R agonist to a next-generation compound and stopping development of PL7737.
Laidlaw
NULL -> Buy
initiated
$60
2025-12-12
Reason
Laidlaw
Price Target
$60
2025-12-12
initiated
NULL -> Buy
Reason
Laidlaw initiated coverage of Palatin with a Buy rating and $60 price target. Palatin (PTN) is a clinical stage biotech company focusing on developing melanocortin receptor based therapeutics, the analyst tells investors in a research note. The firm believes the company's offerings are better than Rhythm Pharmaceuticals' (RYTM) setmelanotide and are very competitive against their next generation follow-on products.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PTN
Unlock Now

People Also Watch